1-3 of 3
Helene A. Yuen
Close
Sort by
Journal Articles

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

Clinical Trials & Observations
Francis J. Giles, Alison T. Stopeck, Lewis R. Silverman, Jeffrey E. Lancet, Maureen A. Cooper, Alison L. Hannah, Julie M. Cherrington, Anne-Marie O'Farrell, Helene A. Yuen, Sharianne G. Louie, Weiru Hong, Jorge E. Cortes, Srdan Verstovsek, Maher Albitar, Susan M. O'Brien, Hagop M. Kantarjian, Judith E. Karp
Journal: Blood
Blood (2003) 102 (3): 795–801.
https://doi.org/10.1182/blood-2002-10-3023
Published: 2003
Journal Articles

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen, Theresa J. Ngai, Sharianne G. Louie, Kevin W. H. Yee, Lily M. Wong, Weiru Hong, Leslie B. Lee, Ajia Town, Beverly D. Smolich, William C. Manning, Lesley J. Murray, Michael C. Heinrich, Julie M. Cherrington
Journal: Blood
Blood (2003) 101 (9): 3597–3605.
https://doi.org/10.1182/blood-2002-07-2307
Published: 2003
Journal Articles

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

Beverly D. Smolich, Helene A. Yuen, Kristina A. West, Francis J. Giles, Maher Albitar, Julie M. Cherrington
Journal: Blood
Blood (2001) 97 (5): 1413–1421.
https://doi.org/10.1182/blood.V97.5.1413
Published: 2001